Context: Signaling lymphocytic activation molecule family 1 (SLAMF1) is a costimulatory receptor expressed by most immune cells. Its role in autoimmune thyroid disease (AITD) is not well known.
Hashimoto thyroiditis (HT), Graves disease (GD), and Graves ophthalmopathy (GO). The interaction of thyroidal follicular cells, antigen-presenting cells, and autoreactive T cells is the main mechanism involved in the development of the autoimmune response against thyroid antigens observed in AITD, which can be mediated by different T helper (Th) cells, mainly Th1, Th2, and Th17 cells (2, 3) . In this regard, for patients with HT, a Th1/ Th17 response predominates, with a strong inflammatory infiltrate in thyroid tissue, which leads to the destruction of the thyroid gland; patients with GD have increased levels of anti-TSH receptors, which are mainly IgG1 and stimulate the thyroid gland's function (4, 5) . Auto-reactive T lymphocytes and thyroidal follicular cells are able to synthesize different cytokines and chemokines, which stimulate the expansion of the intrathyroidal lymphocyte pool and exacerbate the autoimmune process (6) . In addition, AITD patients show different abnormalities in immune regulatory mechanisms, including the levels and function of different T regulatory (Treg) lymphocyte subsets (7) (8) (9) .
The signaling lymphocytic activation molecule family (SLAMF) consists of 9 leukocyte cell surface proteins that belong to the immunoglobulin superfamily (SLAMF1 to SLAMF9), which are expressed on the surface of activated T and B lymphocytes, dendritic cells, macrophages, and mouse hematopoietic stem cells (10) . These receptors exert different functions, including costimulation of T cells (11) (12) (13) , induction of cytokine production (14, 15) , modulation of natural killer (NK) cell-mediated and CD8 T cell-mediated cytotoxicity (16) (17) (18) (19) , differentiation of Th17/Treg cells, and triggering of activationinduced T cell death (20) . In this regard, SLAMF1 has been described as a type I transmembrane self-ligand that plays a relevant role in cell adhesion and signaling mechanisms in the immune synapse between T cells and antigen-presenting cells (APCs). In fact, several reports have observed that this receptor and its adaptorassociated molecule SLAM-associated protein (SAP) are involved in B and T cell costimulation, induction of cytokine synthesis (mainly interferon-g), and differentiation of Th1 lymphocytes (12) (13) (14) (15) .
SLAM family receptors and their intracellular adaptor SAP have been suggested as important mediators in the pathogenesis of autoimmune diseases. In this regard, the loss of the SLAM-SAP signaling pathways due to mutations within the locus encoding SAP (SH2D1A) results in X-linked lymphoproliferative disease, a disorder characterized by a dysregulated immune response to Epstein-Barr virus infection (21) . Furthermore, genomewide linkage analyses of systemic lupus erythematosus (SLE) families have shown a strong association of SLE with the 1q23 region of the human genome, which includes SLAM family receptors (22, 23) . Finally, patients with SLE show an increased expression of SLAMF3 and SLAMF7 in NK cells, B cells, and dendritic cells (23, 24) , which is associated with an increase differentiation of Th17 lymphocytes (21, 25) .
In this study, we analyzed the expression of SLAMF1 by immune cells in peripheral blood and thyroid tissue from patients with AITD as well as the possible effect of SLAMF1 engagement on the suppressive function of Treg cells. Our data suggest that SLAMF1 may contribute to the immune regulatory defects involved in the pathogenesis of AITD.
Materials and Methods

Patients and controls
Twenty-eight patients with AITD (17 patients with GD and 11 patients with HT) and 21 healthy people were included in the study (Table 1) . Patients had a mean age of 47.6 (range, 34 to 61) years, and most of them were female (82%); mean age of controls was 48.6 (range, 35 to 61) years, and 62% of them were female. At the time of the study, 13 patients with GD (76.5%) were receiving antithyroid therapy, and 5 patients with HT (55.6%) were receiving levothyroxine. Five untreated GD patients were studied twice: before start of antithyroid therapy and 3 months later. All patients with GD had a complete eye examination by an ophthalmologist; 12 of them had active ophthalmopathy. In addition, we collected peripheral blood from 5 patients with nonautoimmune hypothyroidism (1 patient with secondary hypothyroidism and 4 with postsurgical hypothyroidism after nodular goiter) and 7 patients with nonautoimmune hyperthyroidism (1 patient with iatrogenic hyperthyroidism due to excessive intake of levothyroxine, 1 patient with acute thyroiditis, 3 patients with toxic adenoma, and 2 with toxic nodular goiter); their age and sex were similar to those of AITD patients and healthy controls.
Blood samples were obtained from all patients and controls, and fresh thyroid tissue samples were obtained from 5 AITD patients, who had been referred for thyroid surgery. Free thyroxine (FT 4 ); thyroid-stimulating hormone (TSH); and antibodies against thyroglobulin, thyroperoxidase, and TSH receptor were assayed as described elsewhere (26) . The Bioethical Committee of the Hospital Universitario de la Princesa approved this study, and a signed informed consent was obtained from all patients and controls.
Cell isolation and flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) of patients and controls were isolated by Ficoll-Hypaque (Lonza Ibérica S.A.U., Barcelona, Spain) density-gradient centrifugation. Thyroid specimens were minced and digested with collagenase (1 mg/mL; Roche Molecular Systems, Pleasanton, CA) for 1 hour at 37°C. Then, cells were passed through a steel mesh (BD Biosciences, San José, CA) and thyroid mononuclear cells were isolated by Ficoll-Hypaque centrifugation. PBMCs 
Inhibition of cell proliferation assays
To analyze the suppressive function of Treg lymphocytes, CD25 + and CD25 2 T cells were isolated by using magnetic beads coupled to an anti-CD25 mAb and MACS MS columns (Miltenyi Biotec, Bergisch Gladbach, Germany). Then, to increase the expression of SLAMF1, CD25 + cells were incubated for 48 hours in the presence of phytohemagglutinin (5.0 mg/mL) (Gibco, Grand Island, NY.) at 37°C in RPMI 1640 with glutaMAX culture medium (Gibco), supplemented with 10% fetal bovine serum and penicillin (100 U/mL)/streptomycin (100 mg/mL). Then, the preactivated CD25 + lymphocytes were incubated or not with 10 mg/mL anti-human SLAMF1 (purified, functional grade; BioLegend) and mixed at a 1:1 ratio with autologous CD25 2 cells, which were preloaded with 5.0 mM carboxyfluorescein succinimidyl ester (Thermo Fisher Scientific, Eugene, OR). These cells were then cultured in 96 flat-bottom well plates (Costar; Corning, NY) that were precoated with 5.0 mg/mL of anti-CD3 (BioLegend) and anti-CD28 (Immunotech, Marseille, France) in OpTmizer CTS T cell expansion basal medium (Gibco). After 5 days at 37°C and 5% CO 2 , cells were harvested and the percentage of 
Immunohistochemical and immunofluorescence analysis
For immunohistochemical evaluation, thyroid tissue sections (4.0-mm thick) were mounted on glass slides (Dako Cytomation, Fort Collins, CO) and stained by an immunoperoxidase method, as previously described (26) . Briefly, endogenous peroxidase was inactivated, and Fc receptors were blocked with diluted goat and human AB serum. Then, sections were incubated with an anti-SLAMF1 (Abcam, Cambridge, MA) monoclonal antibody. Tissue sections were subsequently analyzed in a Nikon Eclipse E400 microscope (Nikon Instruments, Melville, NY). For immunofluorescence analysis, additional sections were incubated with anti-SLAMF1, anti-CD4, anti-CD8, and anti-CD25 mAbs for 1 hour, followed by an Alexa-Fluor 488 antibody or Alexa-Fluor 647 secondary antibody. 4 0 ,6-Diamidino-2-phenylindole dye was used for cell nuclei staining, and sections were analyzed in a Leica TCS-SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany).
Cell cultures
To analyze the effect of the thyroid hormones triiodothyronine (T 3 ) and thyroxine (T 4 ) on PBMC and SLAMF1 expression, we isolated mononuclear cells from 5 healthy controls by using Ficoll-Paque medium (GE Healthcare, Uppsala, Sweden) by density gradient. These cells were then cultured in 96 flat-bottom well plates that were precoated with 5.0 mg/mL of anti-CD3 (BioLegend) and anti-CD28 (Immunotech) at 37°C in RPMI 1640 with glutaMAX culture medium c Standard deviation for TSH in nonautoimmune hypothyroid patients was high because 1 patient had secondary hypothyroidism.
d Negative: ,100 UI/mL.
e Negative, ,344 UI/mL.
and supplemented with 10% fetal bovine serum and penicillin (100 U/mL)/streptomycin (100 mg/mL). Then, cells were incubated or not with 10 ng/mL of T 3 or T 4 (Sigma-Aldrich, St. Louis, MO). After 4 days at 37°C and 5% CO 2 , cells were stained for the expression of SLAMF1 in CD4, Treg, and Th17 lymphocytes, as described previously; they were then acquired in a FACSCanto II cytometer; and, finally, they were analyzed by using FlowJo software.
Statistical analysis
Data are expressed as the arithmetic mean 6 standard deviation or as median and interquartile range, according to their normal or not normal distribution, respectively. Comparisons among groups were performed by using the KruskalWallis test, Student t-test, and one-way analysis of variance tests, as required. Association was analyzed by using the Spearman or Pearson correlation test, according to the normality of the variables studied. All data were analyzed by using GraphPad Prism software, version 5.0 (GraphPad, San Diego, CA).
Results
Expression of SLAMF1 by lymphocytes from patients with AITD
To study the expression of SLAMF1 in different subsets of lymphocytes, we performed a multiparametric analysis by flow cytometry. We found an increased proportion of SLAMF1 + cells in patients with AITD compared with healthy controls [P = 0.02; Fig. 1(A Fig. 1(B), 1(D) , and 1(G)] in blood press.endocrine.org/journal/jcemsamples from patients with AITD compared with controls. However, no significant differences in SLAMF1 expression were found in CD8 + or NK lymphocytes [ Fig. 1 (C) and 1(E)]. Moreover, the expression of SLAMF1 was lower in Treg cells from AITD patients [P = 0.018; Fig. 1(F) ], as well as the Treg/Th17 ratio [P , 0.001; Fig. 1(H) ], compared with controls. Additional analysis revealed that the increased expression of SLAMF1 by whole PBMCs was restricted to patients with GD, whereas patients with HT showed levels similar to those of controls [ Fig. 2(A) ]. However, both GD and HT patients showed an increased proportion of CD4 + SLAMF1
+ cells [ Fig. 2(B) ]. In addition, HT patients, but not those with GD, showed an increased expression of SLAMF1 by Th17 (CD4 + and Th17 lymphocytes from AITD patients [Supplemental Fig. 1(A-C) ]. However, a significantly diminished number of SLAMF1 + Treg cells was observed in these patients [Supplemental Fig. 1(D) ]. Additionally, we analyzed the expression of SLAMF1 in CD4 + lymphocytes from untreated patients with nonautoimmune hypothyroidism and nonautoimmune hyperthyroidism, and we not find significant differences in comparison with healthy controls or AITD patients [P . 0.05; Fig. 1(I) ]. In subsequent analysis, the expression of SLAMF1 in Treg cells and Th17 cells from these patients with nonautoimmune hypothyroidism and nonautoimmune hyperthyroidism was not significantly different in comparison with controls or AITD patients (data not shown). Moreover, we also studied the effect of thyroid hormones (T 3 and T 4 ) on the expression of SLAMF1 in CD4 + , Treg cells, and Th17 cells from 5 healthy controls, but there were no significant differences in the percentage of SLAMF1 in any of these cellular subpopulations before or after the addition of thyroid hormones [Supplemental Fig. 2(A-F) ].
SLAMF1 expression levels and clinical parameters in AITD patients
We also explored the potential association between the expression of SLAMF1 and several clinical and analytical parameters. As shown in Fig. 3(A) , AITD patients with GO tended to show a higher proportion of SLAMF1 + cells compared with those without GO, although this finding did not reach statistical significance. Regarding the relationship with thyroid hormones, we observed a significant negative correlation between SLAMF1 expression by PBMCs and FT 4 levels in GD patients, but not in HT patients or in healthy controls [ Fig. 3(B) and data not shown]. Moreover, in HT patients, a significant positive correlation was detected between the percentage of SLAMF1 + cells in PBMCs and TSH levels [ Fig. 3(C) ].
An additional analysis revealed that untreated GD patients exhibited a diminished expression of SLAMF1 by 
Expression of SLAMF1 in thyroid tissue from patients with AITD
When the expression levels of SLAMF1 were analyzed in mononuclear cells isolated from thyroid tissue from AITD patients by flow cytometry, we observed a significant diminution when compared with those observed in autologous PBMCs [ Fig. 4(A) ]. Accordingly, immunohistochemical and immunofluorescence microscopy analysis revealed a scarce expression of SLAMF1 by the inflammatory cell infiltrate in thyroid tissue from patients with AITD [ Fig. 4 (B) and 4(C)].
Functional role of SLAMF1 in Treg cells from healthy controls and patients with AITD
The functional role of SLAMF1 in CD25 + Treg lymphocytes was analyzed by an inhibition assay of cell proliferation in the peripheral blood from healthy controls and patients with AITD. Thus, the suppressive effect of CD25 + cells on autologous effector lymphocytes was tested in the presence or not of an agonistic anti-SLAMF1 mAb. We found that SLAMF1 engagement induced a significant increase in the suppressive effect of Treg cells from healthy controls [ Fig. 5(A) ]. In contrast, we observed a nonsignificant effect on the addition of the agonistic anti-SLAMF1 mAb in the cell cultures from patients with AITD [ Fig. 5(B) ]. Further analysis revealed that the defective effect of SLAMF1 engagement on Treg cell function was observed in both GD and HT patients, although the latter group exhibited a poorer function of these cells (data not shown).
Discussion
Expression of the SLAMF1 receptor has been observed in different cells of the immune system, including memory/ activated T cells, Th1 helper lymphocytes, B cells, dendritic cells, and thymocytes (13, 27) . Although the precise functional role of this molecule has not been fully elucidated, different reports indicate that it exerts a costimulatory effect on T cells and participates in the activation of B lymphocytes (15) , therefore suggesting that SLAMF1 may be involved in the generation of the adaptive immune response and in the inflammatory phenomenon. Accordingly, several reports have suggested that the SLAM family of receptors is involved in the pathogenesis of autoimmune diseases, mainly SLE (23, 24, 28, 29) . press.endocrine.org/journal/jcem
In this study, we analyzed the expression of SLAMF1 by different immune cell subsets in the peripheral blood and thyroid tissue from AITD patients. Interestingly, we found a significant increase in the expression of this receptor by CD4 + T cells and B lymphocytes from patients with AITD. Because SLAMF1 expression is increased upon lymphocyte activation (30) (31) (32) , it is feasible that the increased numbers of SLAMF1 + cells observed in patients with AITD may be due to the presence of activated autoreactive lymphocytes. Of note, however, we also detected a diminished expression of SLAMF1 by cytotoxic CD8 + lymphocytes in HT patients, a finding that agrees with those of previous studies that reported a decreased expression of other members of the SLAM family by CD8 + T cells from patients with SLE (23, 28, 29) .
Interestingly, we also detected defective expression of SLAMF1 by the CD4 + Foxp3 + Treg cells from AITD patients. In this regard, there are only a few studies regarding the role of SLAMF1 in Treg cells. A possible involvement of this molecule in the tolerogenic effect of immature dendritic cells has been reported, as well as in the in vitro and in vivo generation of CD4 + Foxp3 + Treg cells induced by Taenia solium cysticerci (33, 34) . However, in another study no apparent abnormalities in SLAMF1 expression by Treg cells were observed in patients with SLE, but an apparent increased effect of SLAMF1 engagement on Treg cells from these patients was detected (28) . In contrast, we have observed that Treg cells from patients with AITD show a defective response to SLAMF1 engagement. These results suggest that although SLAMF1 seems to have a complex role on the pathogenesis of autoimmune diseases, their defective function observed in Treg cells from AITD patients may significantly contribute to the immune regulatory aberrations that characterize this condition. Interestingly, in the absence of its associated protein SAP, the costimulatory activity of SLAMF1 in T cells is reverted, exerting an inhibitory effect on the activation and differentiation of B and T lymphocytes (35) . Thus, it would be of interest to assess, through future studies, the expression and function of SAP in lymphocytes from patients with AITD and other autoimmune diseases. Likewise, we believe it would be interesting to elucidate the possible mechanism that accounts for the diminished recruitment of SLAMF1 + cells into the inflammatory cell infiltrate of the thyroid gland from AITD patients. In this regard, it is of interest that other cell subsets are actively recruited into the inflamed thyroid gland, including Treg cells (4, 7), a phenomenon that seems to be mediated by chemokine receptors (mainly CXCR3 and CCR4) and their ligands (6) . Because Th17 cells seem to participate in the pathogenesis of AITD (3), we decided to assess the expression of SLAMF1 in these cells, as it has been previously reported that SLAMF1 engagement favors Th17 differentiation (25, 36) . In this regard, the costimulatory effect of this receptor on T lymphocytes as well as its increased expression in AITD, mainly in HT patients, observed in this study suggest that SLAMF1 may also participate in the induction of differentiation of these cells, thus contributing to the pathogenesis of this condition.
Finally, the significant associations between the levels of expression of SLAMF1 by different cell subsets and clinical and laboratory data are of interest. In this regard, the increased percentage of SLAMF1 + cells observed in GD patients with GO suggest a possible involvement of this receptor in the development of ophthalmopathy in these patients. Moreover, the significant correlations between SLAMF1 expression and FT 4 or TSH levels (observed in GD and HT patients, respectively) suggest a possible role of SLAMF1 + cells on disease severity.
However, the influence of thyroid hormones themselves does not seem to be sufficiently and potentially relevant because we observed that the expression of SLAMF1 in CD4 + , Treg, and Th17 cells did not change significantly after the addition of thyroid hormones to these cells in healthy controls. In addition, patients with nonautoimmune hypo-or hyperthyroidism did not exhibit significant differences in the expression of SALMF1 in comparison with healthy controls. On the other hand, however, we observed significant changes in SLAMF1 expression (increase in Treg cells and decrease in Th17 cells) after therapy with antithyroid drugs. So overall, all these data suggest a complex interaction between the autoimmune response, inflammatory phenomena, disease severity/activity, thyroid hormone levels, and SLAMF1 expression by different cell subsets in AITD. Specifically, it seems that the altered expression of SLAMF1 in several cellular subpopulations may be related to the autoimmune process because the expression of SLAMF1 in nonautoimmune hypo-and hyperthyroidism was not significantly different from that in controls or AITD patients.
Data from our results suggest that SLAMF1 has a key role in the pathogenesis of AITD. However, the genomewide association studies have not yet identified this costimulatory molecule as a susceptibility gene related to these thyroid diseases. In this regard, however, there are 2 other molecules, whose genes are located on chromosome 1, in the same way as SLAMF1 (PTPN22/LYP and FCRL3), that have been already linked to autoimmune disorders, including rheumatoid arthritis and SLE (37) . Therefore, it could be hypothesized that molecules derived from nearby genes in the same chromosome could play similar key roles in the development of autoimmunity. Further investigation is necessary to evaluate the potential involvement of the interesting role that SLAMF1 may have in the development of AITD and other autoimmune disorders.
In summary, we have observed an abnormal pattern of expression of the costimulatory receptor SLAMF1 in immune cells from patients with AITD, as well as a defective function of this receptor in their CD4 + Foxp3 + Treg cells. These phenomena may significantly contribute to the immune regulatory aberrations that characterize AITD and that have a key role in their pathogenesis.
